# Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

> **NCT07385079** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 412 (estimated)

## Conditions studied

- Nasopharyngeal Cancinoma (NPC)
- Nasopharyngeal Cancer

## Interventions

- **DRUG:** Anlotinib Hydrochloride Capsules
- **DRUG:** Gemcitabine (GEM)
- **DRUG:** Cisplatin
- **RADIATION:** Intensity-modulated radiotherapy
- **DRUG:** Benmelstobart

## Key facts

- **NCT ID:** NCT07385079
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2030-01-01
- **Target enrollment:** 412 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07385079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07385079, "Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07385079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*